Incyte Corp (NASDAQ:INCY)

about 10 board members boughs shares today

There are currently 800 INCY shares in my "fund" with break-even of around 2.69 USD. http://caps.fool.com/Blogs/fund-trades/678775.

huge $31.5 MILLION buy by Baker Bros.

Some analysis on Incyte: http://www.iberbiotech.com/incy.html

9/18/11 Options Predictor Rank #12. P/C Ratio 0.015 and Call Sizzle 4.756.

At one point today Incyte stock wasn't far from their one year low. I'm sure that's not what management had in mind for the week that the FDA accepted the NDA for ruxolitinib with a six month priority review. That's a far cry from prices over 20 that were seen earlier in the summer, and it makes Incyte a prime candidate for a rebound given the deep pipeline and hardwired catalyst in early December.

Incyte is entering a critical phase of its transition from a biotech into a pharmaceutical. Having made strategic alliances with big pharma, it has reduced its developmental liabilities while maintaining control of its primary drugs in the US market. As the indications its drugs are targeting have few to no current effective therapies, Incyte will be positioned to gain market share rapidly and expand earnings quickly.

This is a "first-to-the-table" drug for a class of disorders for which current treament is a hassle (periodic large volume bloodletting) or can cause other significant problems (making other blood counts worse, with a risk of bleeding and infection).

I have owned and watched INCY since Oct. 2008 and still think it is a nifty little company with plenty of potential to do good. Maybe it's because I have an orphan disease ... hey, "buy what you know."

New drug for rare blood cancer.

If you saw the news out by the fool today on INCY you would realize they really are foolish. What kind of idiot recycles a story from march and trashes a company is doing all the right things, unless they are short! Do your own homework and you find a great pipeline, collaberations with big pharma and a well develpoed r&d.
<br />&lt;br /&gt;Don't be fooled, get long!

I bought into this stock on 03/05/2010 @ $11.53. So far its one my best performing stocks. My wife works for a CRO (not involved with any INCY's studies) and looked at INCY's pipeline. An effective oral arthritis drug in the pipeline will send this stock thru the roof if it makes it thru phase II trials. Its currently about 3 months into the phase II trial.

GREAT drug development stock.

$1 billion market cap is too big for the pipeline.

good news today on new drug. growth will happeen soon.

Successful JAK2 inhibition has great potential in both hematologic and rheumatologic disease. Being an oral drug could actually be a drawback, as injectable drugs are usually covered by insurances and oral ones less so.

insider buying

As someone who suffers from psoriasis, there are not a lot of effective treatments on the market. Incyte's drug candidate for Psoriasis will do very well once it has FDA approval and if they also get approval for a topical solution to treat mild to moderate psoriasis this could be a home run revenue producer.

INCY DIABETIC DRUG COULD BE WORTH A BILLION DOLLARS
THEY ALSO HAVE A FEW OTHER DRUGS COMING UP WORTH THE SAME AMOUNT, A BILLION DOLLAR COMPANY IN THE WORKS.